{"id":3284,"date":"2021-06-15T00:24:26","date_gmt":"2021-06-15T00:24:26","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=3284"},"modified":"2023-08-29T17:49:52","modified_gmt":"2023-08-29T17:49:52","slug":"invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=3284","title":{"rendered":"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988"},"content":{"rendered":"<p>\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002<\/p>\n<p>\u4eca\u5e743\u6708\uff0c\u8be5\u516c\u53f8\u5411FDA\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u65b9\u6848\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\uff0c\u4ee5\u53ca\u4e00\u4e9b\u95ee\u9898\u3002<\/p>\n<p>\u8fd9\u4e9b\u6587\u4ef6\u5bfb\u6c42FDA\u5bf9\u603b\u4f53\u7814\u7a76\u8bbe\u8ba1\u7684\u6307\u5bfc\uff0c\u5e76\u5c06\u9885\u5185\u538b\u548c\u5934\u75db\u4f5c\u4e3a\u4e3b\u8981\u7ec8\u70b9\u3002<\/p>\n<h2>\u9009\u62e9\u7aef\u70b9<\/h2>\n<p>FDA\u5df2\u7ecf\u56de\u590d\u4e86\u4e00\u7ec4\u4e66\u9762\u56de\u590d\uff0c\u5efa\u8baeInvex\u8003\u8651\u5c06\u89c6\u89c9\u529f\u80fd\u7684\u201c\u4e34\u5e8a\u610f\u4e49\u6548\u5e94\u201d\u4f5c\u4e3a\u66ff\u4ee3\u4e3b\u8981\u7ec8\u70b9\u3002<\/p>\n<p>\u5b83\u63d0\u51fa\u4e86\u5468\u8fb9\u5e73\u5747\u504f\u5dee\u2014\u2014\u8fd9\u662f\u4e00\u79cd\u8861\u91cf\u60a3\u8005\u89c6\u91ce\u53d8\u5316\u7684\u65b9\u6cd5\u2014\u2014\u5e76\u5bf9Invex\u63d0\u4f9b\u7684preendin(\u539fExenatide)\u5982\u4f55\u6539\u5584\u8fd9\u4e00\u95ee\u9898\u7684\u5efa\u8bae\u6301\u5f00\u653e\u6001\u5ea6\u3002<\/p>\n<p>FDA\u8ba4\u4e3a\u9885\u5185\u538b\u662f\u8be5\u7814\u7a76\u5408\u9002\u7684\u6b21\u8981(\u800c\u975e\u4e3b\u8981)\u7ec8\u70b9\uff0c\u8fd9\u4e0eInvex\u4e4b\u524d\u4ece\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40(EMA)\u83b7\u5f97\u7684\u5efa\u8bae\u5f62\u6210\u4e86\u5bf9\u6bd4\u3002<\/p>\n<p>\u5173\u4e8e\u8ba1\u5212\u4e2d\u7684\u6bcf\u6708\u5934\u75db\u5929\u6570\uff0c\u5f88\u5c11\u6709\u5177\u4f53\u7684\u8bc4\u8bba\uff0c\u4f46\u662fFDA\u786e\u5b9e\u63a8\u8350\u4e86\u4e00\u4e2a\u7b80\u5316\u7684\u5934\u75db\u4e25\u91cd\u7a0b\u5ea6\u91cf\u8868\u4f5c\u4e3a\u66ff\u4ee3\u8bc4\u4f30\u3002<\/p>\n<h2>\u6f5c\u5728\u7684\u5ba1\u6279\u8def\u5f84<\/h2>\n<p>Invex\u8463\u4e8b\u957fDr Jason Loveridge\u8868\u793a\uff0cFDA\u7684\u53cd\u9988\u5c06\u8fdb\u4e00\u6b65\u544a\u77e5\u516c\u53f8Presendin\u4f5c\u4e3aIIH\u6cbb\u7597\u836f\u7269\u53ef\u80fd\u5728\u7f8e\u56fd\u83b7\u5f97\u6279\u51c6\u3002<\/p>\n<p>\u4ed6\u8bf4:\u201c\u6211\u4eec\u7684\u4e34\u5e8a\u8bd5\u9a8c\u65b9\u6848\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\u8bd5\u56fe\u901a\u8fc7\u7eb3\u5165\u6700\u80fd\u53cd\u6620\u75be\u75c5\u7279\u5f81\u548c\u5934\u75db\u5bf9\u60a3\u8005\u751f\u6d3b\u8d28\u91cf\u7684\u5e7f\u6cdb\u5f71\u54cd\u7684\u5173\u952e\u7ec8\u70b9\u6765\u534f\u8c03\u548c\u83b7\u5f97EMA\u548cFDA\u4e4b\u95f4\u7684\u5e7f\u6cdb\u5171\u8bc6\u3002\u201d<\/p>\n<p>\u201c\u5728\u5176\u56de\u5e94\u4e2d\uff0c\u795e\u7ecf\u75c5\u5b66\u90e8\u95e8\u91cd\u590d\u4e86\u6700\u521d\u7684\u773c\u79d1\u90e8\u95e8\u7684\u53cd\u9988\uff0c\u5373\u89c6\u89c9\u529f\u80fd\u5e94\u8be5\u662f\u4e00\u9879\u5bfb\u6c42\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u6cbb\u7597\u836f\u7269\u6279\u51c6\u7684\u7814\u7a76\u7684\u5173\u952e\u7ed3\u679c\u6307\u6807\u3002\u201d<\/p>\n<p>Dr Loveridge\u8868\u793a\uff0c\u516c\u53f8\u5c06\u5728\u672a\u6765\u51e0\u5468\u4f1a\u89c1\u5173\u952e\u7684\u76d1\u7ba1\u548c\u4e34\u5e8a\u987e\u95ee\uff0c\u4ee5\u66f4\u597d\u5730\u4e86\u89e3FDA\u7684\u53cd\u5e94\uff0c\u5e76\u786e\u5b9a\u7814\u7a76\u7684\u6700\u4f73\u65b9\u5411\u548c\u8bbe\u8ba1\u3002<\/p>\n<h2>\u63d0\u9ad8\u538b\u529b\u6c34\u5e73<\/h2>\n<p>\u8111\u51fa\u8840\u7684\u7279\u70b9\u662f\u9885\u9aa8\u5185\u538b\u4e25\u91cd\u5347\u9ad8\uff0c\u8fd9\u53ef\u80fd\u5bfc\u81f4\u60a3\u8005\u51fa\u73b0\u8111\u7624\u7684\u75c7\u72b6\u548c\u4f53\u5f81\uff0c\u5305\u62ec\u8870\u5f31\u7684\u65e5\u5e38\u5934\u75db\u548c\u89c6\u795e\u7ecf\u53d7\u538b\u3002<\/p>\n<p>\u901a\u5e38\u51fa\u73b0IIH\u7684\u5e74\u9f84\u572820 &#8211; 30\u5c81\u4e4b\u95f4\uff0c\u7edf\u8ba1\u4e0a\u8fd9\u79cd\u60c5\u51b5\u5728\u80a5\u80d6\u7684\u5973\u6027\u4e2d\u6700\u5e38\u89c1\u3002<\/p>\n<p>IIH\u88ab\u8ba4\u4e3a\u662f\u4e00\u79cd\u5feb\u901f\u751f\u957f\u7684\u5b64\u513f\u9002\u5e94\u75c7\u3002<\/p>\n<p>\u5b83\u7684\u53d1\u75c5\u7387\u5728\u8fc7\u53bb10\u5e74\u589e\u52a0\u4e86350%\u4ee5\u4e0a\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002 \u4eca\u5e743\u6708\uff0c\u8be5\u516c\u53f8\u5411FDA\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u65b9\u6848\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\uff0c\u4ee5\u53ca\u4e00\u4e9b\u95ee\u9898\u3002 \u8fd9\u4e9b\u6587\u4ef6\u5bfb\u6c42FDA\u5bf9\u603b\u4f53\u7814\u7a76\u8bbe\u8ba1\u7684\u6307\u5bfc\uff0c\u5e76\u5c06\u9885\u5185\u538b\u548c\u5934\u75db\u4f5c\u4e3a\u4e3b\u8981\u7ec8\u70b9\u3002 \u9009\u62e9\u7aef\u70b9 FDA\u5df2\u7ecf\u56de\u590d\u4e86\u4e00\u7ec4\u4e66\u9762\u56de\u590d\uff0c\u5efa\u8baeInvex\u8003\u8651\u5c06\u89c6\u89c9\u529f\u80fd\u7684\u201c\u4e34\u5e8a\u610f\u4e49\u6548\u5e94\u201d\u4f5c\u4e3a\u66ff\u4ee3\u4e3b\u8981\u7ec8\u70b9\u3002 \u5b83\u63d0\u51fa\u4e86\u5468\u8fb9\u5e73\u5747\u504f\u5dee\u2014\u2014\u8fd9\u662f\u4e00\u79cd\u8861\u91cf\u60a3\u8005\u89c6\u91ce\u53d8\u5316\u7684\u65b9\u6cd5\u2014\u2014\u5e76\u5bf9Invex\u63d0\u4f9b\u7684preendin(\u539fExenatide)\u5982\u4f55\u6539\u5584\u8fd9\u4e00\u95ee\u9898\u7684\u5efa\u8bae\u6301\u5f00\u653e\u6001\u5ea6\u3002 FDA\u8ba4\u4e3a\u9885\u5185\u538b\u662f\u8be5\u7814\u7a76\u5408\u9002\u7684\u6b21\u8981(\u800c\u975e\u4e3b\u8981)\u7ec8\u70b9\uff0c\u8fd9\u4e0eInvex\u4e4b\u524d\u4ece\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40(EMA)\u83b7\u5f97\u7684\u5efa\u8bae\u5f62\u6210\u4e86\u5bf9\u6bd4\u3002 \u5173\u4e8e\u8ba1\u5212\u4e2d\u7684\u6bcf\u6708\u5934\u75db\u5929\u6570\uff0c\u5f88\u5c11\u6709\u5177\u4f53\u7684\u8bc4\u8bba\uff0c\u4f46\u662fFDA\u786e\u5b9e\u63a8\u8350\u4e86\u4e00\u4e2a\u7b80\u5316\u7684\u5934\u75db\u4e25\u91cd\u7a0b\u5ea6\u91cf\u8868\u4f5c\u4e3a\u66ff\u4ee3\u8bc4\u4f30\u3002 \u6f5c\u5728\u7684\u5ba1\u6279\u8def\u5f84 Invex\u8463\u4e8b\u957fDr Jason Loveridge\u8868\u793a\uff0cFDA\u7684\u53cd\u9988\u5c06\u8fdb\u4e00\u6b65\u544a\u77e5\u516c\u53f8Presendin\u4f5c\u4e3aIIH\u6cbb\u7597\u836f\u7269\u53ef\u80fd\u5728\u7f8e\u56fd\u83b7\u5f97\u6279\u51c6\u3002 \u4ed6\u8bf4:\u201c\u6211\u4eec\u7684\u4e34\u5e8a\u8bd5\u9a8c\u65b9\u6848\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\u8bd5\u56fe\u901a\u8fc7\u7eb3\u5165\u6700\u80fd\u53cd\u6620\u75be\u75c5\u7279\u5f81\u548c\u5934\u75db\u5bf9\u60a3\u8005\u751f\u6d3b\u8d28\u91cf\u7684\u5e7f\u6cdb\u5f71\u54cd\u7684\u5173\u952e\u7ec8\u70b9\u6765\u534f\u8c03\u548c\u83b7\u5f97EMA\u548cFDA\u4e4b\u95f4\u7684\u5e7f\u6cdb\u5171\u8bc6\u3002\u201d \u201c\u5728\u5176\u56de\u5e94\u4e2d\uff0c\u795e\u7ecf\u75c5\u5b66\u90e8\u95e8\u91cd\u590d\u4e86\u6700\u521d\u7684\u773c\u79d1\u90e8\u95e8\u7684\u53cd\u9988\uff0c\u5373\u89c6\u89c9\u529f\u80fd\u5e94\u8be5\u662f\u4e00\u9879\u5bfb\u6c42\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u6cbb\u7597\u836f\u7269\u6279\u51c6\u7684\u7814\u7a76\u7684\u5173\u952e\u7ed3\u679c\u6307\u6807\u3002\u201d Dr Loveridge\u8868\u793a\uff0c\u516c\u53f8\u5c06\u5728\u672a\u6765\u51e0\u5468\u4f1a\u89c1\u5173\u952e\u7684\u76d1\u7ba1\u548c\u4e34\u5e8a\u987e\u95ee\uff0c\u4ee5\u66f4\u597d\u5730\u4e86\u89e3FDA\u7684\u53cd\u5e94\uff0c\u5e76\u786e\u5b9a\u7814\u7a76\u7684\u6700\u4f73\u65b9\u5411\u548c\u8bbe\u8ba1\u3002 \u63d0\u9ad8\u538b\u529b\u6c34\u5e73 \u8111\u51fa\u8840\u7684\u7279\u70b9\u662f\u9885\u9aa8\u5185\u538b\u4e25\u91cd\u5347\u9ad8\uff0c\u8fd9\u53ef\u80fd\u5bfc\u81f4\u60a3\u8005\u51fa\u73b0\u8111\u7624\u7684\u75c7\u72b6\u548c\u4f53\u5f81\uff0c\u5305\u62ec\u8870\u5f31\u7684\u65e5\u5e38\u5934\u75db\u548c\u89c6\u795e\u7ecf\u53d7\u538b\u3002 \u901a\u5e38\u51fa\u73b0IIH\u7684\u5e74\u9f84\u572820 &#8211; 30\u5c81\u4e4b\u95f4\uff0c\u7edf\u8ba1\u4e0a\u8fd9\u79cd\u60c5\u51b5\u5728\u80a5\u80d6\u7684\u5973\u6027\u4e2d\u6700\u5e38\u89c1\u3002 IIH\u88ab\u8ba4\u4e3a\u662f\u4e00\u79cd\u5feb\u901f\u751f\u957f\u7684\u5b64\u513f\u9002\u5e94\u75c7\u3002 \u5b83\u7684\u53d1\u75c5\u7387\u5728\u8fc7\u53bb10\u5e74\u589e\u52a0\u4e86350%\u4ee5\u4e0a\u3002<\/p>\n","protected":false},"author":4,"featured_media":12061,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988<\/title>\n<meta name=\"description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988\" \/>\n<meta property=\"og:description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-15T00:24:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:49:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-US-Food-and-Drug-Administration-FDA-Division-of-Neurology-Type-C-Meeting-clinical-trial-Presendin-Exenatide-treatment-Idiopathic-Intracranial-Hypertension.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988\" \/>\n<meta name=\"twitter:description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/\",\"name\":\"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2021-06-15T00:24:26+00:00\",\"dateModified\":\"2023-08-29T17:49:52+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988","description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988","og_description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/","og_site_name":"smallcapsCN","article_published_time":"2021-06-15T00:24:26+00:00","article_modified_time":"2023-08-29T17:49:52+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-US-Food-and-Drug-Administration-FDA-Division-of-Neurology-Type-C-Meeting-clinical-trial-Presendin-Exenatide-treatment-Idiopathic-Intracranial-Hypertension.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_title":"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988","twitter_description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/","name":"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2021-06-15T00:24:26+00:00","dateModified":"2023-08-29T17:49:52+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u8fd1\u65e5\u6536\u5230\u4e86\u6765\u81ea\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u795e\u7ecf\u5185\u79d1\u90e8\u95e8\u7684\u4e66\u9762\u53cd\u9988\uff0c\u8be5\u53cd\u9988\u6d89\u53ca\u5148\u5bfc\u836f\u7269Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u62df\u8bae\u8bbe\u8ba1\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-us-fda-feedback-presendin-trial-idiopathic-intracranial-hypertension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics\u6536\u5230\u7f8e\u56fdFDA\u5173\u4e8e\u8ba1\u5212\u4e2d\u9488\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684Presendin\u8bd5\u9a8c\u7684\u53cd\u9988"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/3284"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3284"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/3284\/revisions"}],"predecessor-version":[{"id":12060,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/3284\/revisions\/12060"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/12061"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}